Relationships between Myocardial Damage Biomarkers with Infarct Size and Ejection Fraction Impairment Assessed by Cardiac Magnetic Resonance | Chapter 8 | New Frontiers in Medicine and Medical Research Vol. 8

 Acute myocardial infarction (AMI) is the most common cause of illness and mortality in the globe. The largest predictors of post-AMI mortality are the final infarct size (FIS) and left ventricular ejection fraction (LVEF), with cardiac magnetic resonance (CMR) being the gold standard method for measuring them. Biomarkers for myocardial injury, such as creatine kinase (CK) and myocardial creatine kinase (CKMB), are currently utilised to diagnose AMI and quantify the amount of myocardial damage. It would be reasonable to employ them as predictors of FIS and LVEF; however, present evidence is lacking.

On the basis of their correlation in patients having primary coronary angioplasty (PCA) following ST-elevation acute myocardial infarction, establish the potential power of plasma CK and CKMB levels as predictors of FIS and LVEF deterioration, respectively (STEMI).

The PREVEC Trial (ISRCTN registry: 56034553), a multicentric, randomised, double-blind clinical research, was retrospectively examined. Sixty-seven individuals with STEMI who were scheduled for PCA were included in the study. The CMR was done 7 to 15 days after the incident. FIS and LVEF were measured by three radiologists who were blinded to clinical information. At 6-8 hours after PCA, total CK and CKMB were assessed in peripheral venous blood. The correlation coefficients were calculated, and the tests were deemed significant when the p value was less than 0.05. The statistical analysis was performed using the software GraphPrism 6.0.

The levels of cardiac biomarkers were shown to have a substantial positive connection with FIS [total CK (r-square 0.3, p0.0001) and CK MB (r-square 0.15, p0.0027)]. Furthermore, there was a strong negative connection between the levels of these biomarkers and LVEF [total CK (r-square 0.3, p0.0001) and CK MB (r-square 0.18, p0.0012)].

Conclusion: These findings support the notion that the myocardial damage biomarkers CK and CKMB are accurate predictors of FIS and LVEF in post-AMI patients evaluated by CMR. These findings point to the possibility of these biomarkers being incorporated in future Risk Scores.

Author (S) Details

Lucía Del Valle-Batalla
Faculty of Medicine, University of Chile, Chile.

Raúl Castillo-Astorga
Faculty of Medicine, University of Chile, Chile.

Rodolfo Prieto-Riveros
Faculty of Medicine, University of Chile, Chile.

Jaime González
Faculty of Medicine, Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Chile.

Rubén Aguayo
San Juan de Dios Hospital, Santiago, Chile.

Kjersti Nes
San Juan de Dios Hospital, Santiago, Chile.

Cristóbal Ramos
University of Chile Clinical Hospital, Santiago, Chile.

Juan Carlos Prieto
University of Chile Clinical Hospital, Santiago, Chile.

Ramón Rodrigo
Faculty of Medicine, Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Chile.

View Book :- https://stm.bookpi.org/NFMMR-V8/article/view/3111